1. Notal Vision Welcomes Roni Amiel as Chief Information Officer

    Notal Vision Welcomes Roni Amiel as Chief Information Officer

    Notal Vision, Ltd., a privately-held ophthalmic company focused on cloud-based, patient-activated, home telemonitoring technologies, is pleased to announce the appointment of Roni Amiel as Chief Information Officer (CIO). In this newly created position, Mr. Amiel will be responsible for advancing the Company's cloud-based technology and capabilities to expand their competitive advantage, and will report to Quinton Oswald, Chief Executive Officer of Notal Vision.

    "Drawing on his extensive information technology (IT) leadership and medical systems expertise, Roni will help us execute our strategic goals so that we can continue to deliver an outstanding patient and physician experience. Elevating this IT leadership role to my executive team ensures we are placing the critical emphasis needed to develop and expand our capabilities for both ForeseeHome®, the first home monitoring system for age-related macular degeneration (AMD), and the Notal Home OCT, our home-based optical coherence tomography (OCT) platform, which is in development," commented Mr. Oswald. "The addition of Roni as CIO represents another step forward as we build a world-class leadership team to drive Notal's growth as the pioneer in home-based telemonitoring for ocular diseases."

    "I am thrilled to join Notal Vision at this important time in the Company's evolution," said Mr. Amiel. "Notal has established a proven, cloud-based platform for home-based disease monitoring with ForeseeHome. The model utilizes an Independent Diagnostic Testing Facility supported by clinically validated technology and a robust, proprietary IT infrastructure. Notal's next home-based telemonitoring application, the Notal Home OCT, may have the potential to expand the patient groups who benefit from ophthalmic telemedicine beyond wet AMD, to include diabetic macular edema, branch retinal vein occlusion, post-operative macular edema in high-risk patients, and myopic choroidal neovascularization. I look forward to working with the team to continue to define and strengthen Notal Vision's leadership position in the growing telehealth sector."

    Mr. Amiel has more than 20 years of information systems leadership and brings extensive expertise of IT initiatives to this role. His most recent experience was at Frost Data Capital, which provides ideation, investment, and incubation to launch and scale startups. Prior to this, he was at Healthcare Analytics, where he was Chief Technology Officer and Chief Information Securing Officer. He was also the Chief Information Officer and Chief Information Security Officer for Blythedale Children's Hospital in New York. Mr. Amiel earned his Bachelor of Science in Business Administration with a concentration in Information Technology from Colorado Technical University and his Masters in Biomedical and Informatics from Rutgers University.

    About Notal Vision's Home-based Telemonitoring Platforms

    Notal Vision has established a seamless, cloud-based infrastructure that connects healthcare providers and their patients through personalized, home-based detection and monitoring of ocular diseases.  ForeseeHome®, the first application of Notal Vision's cloud-based platform, is an FDA-cleared home  telemonitoring system for patients at risk of vision loss from wet AMD. It utilizes a patented technology which is based upon Preferential Hyperacuity Perimetry (PHP) to detect visual distortions, often before the patient notices any visual symptoms. ForeseeHome was evaluated in over 1,500 patients in the HOME study and demonstrated detection of choroidal neovascularization (CNV) at better levels of vision compared to standard care methods.  In the study, office visits triggered using ForeseeHome were 16 times more likely to detect wet AMD than regularly scheduled office visits alone.  Additionally, 94% of patients who progressed to wet AMD with the use of ForeseeHome kept their functional vision (20/40) versus 62% of patients using other detection methods. ForeseeHome is covered by Medicare and most private insurances. To learn more, visit http://www.foreseehome.com.

    The Notal Home OCT (optical coherence tomography) will be the next platform to utilize Notal's cloud-based information technology system. It will enable patients to perform technician-free OCT at home with appropriate fixation – a critical component, especially for elderly patients. The Notal OCT Analyzer (NOA), a proprietary algorithm developed by an in-house engineering team, performs automated analysis of the Notal Home OCT scans and generates an alert to the physician once fluid is present. The NOA sends the top three scans to the physician for review, at which point, the patient may be brought to the office for evaluation and treatment. The Notal Home OCT has demonstrated high sensitivity, specificity, and accuracy and has the potential to truly individualize retinal disease management.

    About Notal Vision™

    Notal Vision was founded by two ophthalmologists, and is committed to providing the eyecare community with innovative, home-based, technology solutions that support visual health in patients with retinal diseases.  The company's ForeseeHome® device is the first FDA-cleared home telemonitoring device that detects and characterizes visual distortion in AMD patients as an aid to monitoring choroidal neovascularization progression. To learn more, visit http://www.foreseehome.com/about-notal.html.

    Login to comment.

  1. Categories

    1. Applications:

      Art, Cardiology, Dentistry, Dermatology, Developmental Biology, Gastroenterology, Gynecology, Microscopy, NDE/NDT, Neurology, Oncology, Ophthalmology, Other Non-Medical, Otolaryngology, Pulmonology, Urology
    2. Business News:

      Acquisition, Clinical Trials, Funding, Other Business News, Partnership, Patents
    3. Technology:

      Broadband Sources, Probes, Tunable Sources
    4. Miscellaneous:

      Jobs & Studentships, Student Theses, Textbooks
  2. Topics Mentioned

  3. Authors